24-10-2019
II Studio / Shutterstock.com
The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Brazilian Federal Public Defender’s Office, hepatitis C, Gilead, patents, drug pricing, Administrative Council for Economic Defence
Brazil rules 10-year patent term ‘unconstitutional’
11-05-2021
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16-02-2021
PTAB to review Minnesota patent after Gilead petition
02-06-2020
Fed Circuit sides with Gilead over hep C patent
31-10-2019
Brazilian court suspends Gilead patent after presidential candidate request
27-09-2018
